A collage photo of Timothée Olivier, Alyson Haslam and Vinay Prasad.
Jun 24, 2024, 01:26
Timothée Olivier: Postrecurrence Treatment in Neoadjuvant or Adjuvant FDA Registration Trials
Timothée Olivier, Medical Oncologist at HUG – Geneva University Hospitals, shared a post on X:
“Our new paper out in JAMA Oncology! Co-authored with Alyson Haslam and Vinay Prasad
‘Is it better to treat all patients early on, or to spare those who are already cured and only treat those who relapse?’ Here are some clues, and my coverage of our work.”
Source: Timothée Olivier/X
Timothée Olivier is a medical oncologist at the Oncology Division of Geneva University Hospital in Switzerland. He also serves as a visiting researcher at the University of California, San Francisco. His research focuses on meta-research, evidence-based medicine, health policy, drug regulation, quality of life, medical education, and screening.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 12, 2024, 23:10
Nov 12, 2024, 23:07
Nov 12, 2024, 22:58
Nov 12, 2024, 22:56
Nov 12, 2024, 22:50
Nov 12, 2024, 22:46
Nov 12, 2024, 22:43